- Home
- CFFI vs VCRE Comparison
CFFI vs VCRE Comparison
Compare CFFI & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CFFI | VCRE |
|---|---|---|
| Founded | 1927 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.3M | 271.7M |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CFFI | VCRE |
|---|---|---|
| Price | $101.51 | $8.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.8K | 22.9K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 37.94 | N/A |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $140,841,000.00 | N/A |
| Revenue This Year | N/A | $119.57 |
| Revenue Next Year | $9.45 | $508.89 |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $65.95 | $7.88 |
| 52 Week High | $103.04 | $13.15 |
Technical Indicators
Market Signals| Indicator | CFFI | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 38.01 |
| Support Level | $69.33 | N/A |
| Resistance Level | N/A | $12.63 |
| Average True Range (ATR) | 2.71 | 0.89 |
| MACD | 0.59 | -0.11 |
| Stochastic Oscillator | 92.03 | 21.12 |
Price Performance
Historical ComparisonAbout CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.